Accelr8 Technology Corporation (NYSE MKT: AXK) announced results of two studies that it presented at the 112 th annual General Meeting of the American Society for Microbiology ( www.asm.org).
The first study used the company’s BACcel™ rapid automated diagnostic system with positive blood cultures to detect a major, complex multi-drug resistance expression type known as “ESBL.” The system’s 3-hour results showed the benefits of the platform decreasing time to result by 1-2 days over the best standard method while maintaining 100% sensitivity and 94% specificity. ESBL resistance has spread globally with hundreds of molecular variants. Early ESBL spread occurred in hospitals, but is now reaching into community-acquired infections. These resistance types are difficult to detect and severely reduce treatment options in the largest family of Gram-negative pathogens.
The second study reported performance of the company’s rapid, fully automated specimen preparation technology. It showed that in 10 minutes or less, the BAC-Xtrax™ gel electrofiltration system concentrates live bacteria and substantially clears the sample from complex interference. The BAC-Xtrax™ concentrated live cells more than 100-fold from the original samples, exceeding the best standard method by more than 10 times. It recovered essentially all of the organisms in the samples, with variation comparable to that of the quantitative culturing reference method.
Separately, Accelr8 also received notice of acceptance to present results at ICAAC 2012 for a new study entitled “Same-Day Blood Culture with Digital Microscopy.” The study examines alternatives for shortening the currently typical overnight delay for cultures before beginning analysis of blood-borne infections.About Accelr8 Accelr8 Technology Corporation ( www.accelr8.com) is a developer of innovative materials and instrumentation for advanced applications in medical instrumentation, basic research, drug discovery, and bio-detection. Accelr8 is developing a rapid analytical platform for infectious pathogens, the BACcel™ system, based on its innovative assay processing and detection technologies. In addition, Accelr8 licenses certain of its proprietary technology for use in applications outside of Accelr8’s own products. Certain statements in this news release may be “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the company's filings with the Securities and Exchange Commission. Accelr8 does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.